ABCAM PLC Acquisition of Marker Gene Technologies (9207E)
04 March 2020 - 6:00PM
UK Regulatory
TIDMABC
RNS Number : 9207E
ABCAM PLC
04 March 2020
4 March 2020
ABCAM PLC
("Abcam" or "the Company")
Abcam extends assay and labelling capabilities with the
acquisition of Marker Gene Technologies
Abcam (AIM: ABC), a global innovator in life science reagents
and tools, today announces the acquisition of the entire issued
share capital of Marker Gene Technologies, Inc. ("MGT") (the
"Acquisition").
Following the recent acquisition of Expedeon's proteomics and
immunology business, and aligned with our broader
antibody-conjugation strategy, the acquisition of MGT brings
additional proprietary assay development technologies and labelling
capabilities to Abcam. MGT's team have expertise in the areas of
biology, organic synthesis and fluorescence chemistry and are
experienced in the creation of detection tools that enable enhanced
understanding of biological processes.
Financial terms of the Acquisition have not been disclosed and
are expected to have a minimal impact on revenue and earnings in
the current financial year.
A substantial portion of the consideration for the Acquisition
will be funded from newly issued Abcam shares. An application has
been made to AIM for the admission to trading of 49,416 new
ordinary shares of 0.2p each in the Company (the "New Ordinary
Shares"). The New Ordinary Shares are expected to be admitted to
trading on or around 9 March 2020 and will, when issued, rank pari
passu with the Company's existing ordinary shares.
As at 4 March 2020, the Company's issued share capital consists
of 206,082,681 ordinary shares of 0.2p each. The Company does not
hold any shares in treasury. The total number of voting rights in
the Company is therefore 206,082,681.
The above figure of 206,082,681 should be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the Company, under the Disclosure and
Transparency Rules.
Following admission of the New Ordinary Shares on or around 9
March 2020, the Company's issued and fully paid share capital will
consist of 206,132,097 ordinary shares of 0.2p each.
--ENDS--
For further information, please contact:
Abcam
+ 44 (0) 1223 696 000
Investors: James Staveley, VP Investor
Relations
Media Lynne Trowbridge, VP External
Relations
FTI Consulting
+44 (0) 20 3727 1000 Ben Atwell / Natalie Garland-Collins
About Abcam plc
As a global life sciences company, Abcam identifies, develops,
and distributes high-quality biological reagents and tools that are
crucial to research, drug discovery and diagnostics. Working across
the industry, the Company supports life scientists to achieve their
mission, faster.
Abcam partners with life science organizations to co-create
novel binders for use in drug discovery, in vitro diagnostics and
therapeutics, driven by the Company's proprietary discovery
platforms and world-leading, antibody expertise.
By constantly innovating its binders and assays, Abcam is
helping advance the global understanding of biology and causes of
disease, which enables new treatments and improved health. The
Company's pioneering data-sharing approach gives scientists
increased confidence in their results by providing validation, user
comments and peer-reviewed citations for its 110,000 products.
With eleven sites globally, many of Abcam's 1,100 strong team
are located in the world's leading life science research hubs,
complementing a global network of services and support.
To find out more, please visit www.abcam.com and
www.abcamplc.com .
Forward looking statements
This announcement, including any information included or
incorporated by reference in this announcement, may contain
forward-looking statements (including words such as "believe",
"expect", "estimate", "intend", "anticipate" and words of similar
meaning) which are based upon current expectations and assumptions
regarding anticipated developments and other factors affecting the
Abcam Group. All statements other than statements of historical
facts may be forward-looking statements and should not be treated
as guarantees of future performance. These forward-looking
statements involve risks and uncertainties, many of which are
beyond the control of the Abcam Group, and there are important
factors that could cause actual results to differ materially from
those expressed or implied by these forward-looking statements.
These forward-looking statements speak only as at the date of this
announcement and accordingly undue reliance should not be placed on
such statements. The Abcam Group does not assume any obligation to,
and does not intend to, revise or update these forward-looking
statements, except as required pursuant to applicable law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACQUPUAGWUPUPPW
(END) Dow Jones Newswires
March 04, 2020 02:00 ET (07:00 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024